medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Number 3

<< Back Next >>

Ann Hepatol 2011; 10 (3)

Prophylactic and curative effects of purslane on bile duct ligation-induced hepatic fibrosis in albino rats

Ali SI, Said MM, Mohammed HEK

Language: English
References: 42
Page: 340-346
PDF size: 94.24 Kb.


ABSTRACT

Introduction. Hepatic fibrosis is a common pathological process of chronic liver injury. Oxidative stress and inflammation may have prognostic value in disease progression. Objective. To examine the implication of both aforementioned factors in hepatic fibrosis progression and whether, the antioxidant effect of various biological active constituents such as phenolic, flavonoids and fatty acids of purslane hydro-ethanolic extract can represent a potential target for therapy. Methods. Purslane exhibited a considerable antioxidant potential in DPPH assay compared to α-tocopherol. Consequently, the current study was designed to examine the prophylactic and curative effects of purslane extract on bile duct ligation (BDL)-induced liver fibrosis in rats in comparison with silymarin as a reference hepatoprotective agent. Purslane (400 mg/kg/ day) or silymarin (50 mg/kg/day) were administered orally for 4 weeks, immediately after surgery in order to evaluate the prophylactic effect and for 3 weeks starting 3 weeks after BDL in order to evaluate the curative effect. BDL significantly increased liver enzymes, total bilirubin (TB) and tumor necrosis factor-alpha (TNF-α) in serum along with malondialdehyde (MDA) in liver tissues. Results. Significant decrease in hepatic antioxidant defense system was noted in BDL-rats. Conversely, administration of purslane reversed all these biochemical parameters which were previously induced by BDL. Considerably, purslane effect was more pronounced in the prophylactic study than that in the curative one. Conclusion. The present work suggested that purslane had prophylactic and curative value on cholestasis-induced liver fibrosis through inhibition of oxidative stress, decreasing the expression of profibrogenic cytokines, collagenolytic activity and activation of hepatic stellate cells.


REFERENCES

  1. Thakare SP, Jain HN, Patil SD, Upadhyay UM. Hepatoprotective effect of Cocculus hirsutus on bile duct ligationinduced liver fibrosis in Albino Wistar rats. Bangladesh J Pharmacol 2009; 4: 126-30.

  2. Hong JY, Sato EF, Hiramoto K, Nishikawa M, Inoue M. Mechanism of liver injury during obstructive jaundice: role of nitric oxide, splenic cytokines, and intestinal flora. J Clin Biochem Nutr 2007; 40: 184-93.

  3. López-Sánchez LM, Corrales FJ, Barcos M, Espejo I, Juan R Muòoz-Castaòeda, Rodríguez-Ariza A. Inhibition of nitric oxide synthesis during induced cholestasis ameliorates hepatocellular injury by facilitating S-nitrosothiol homeostasis. Lab Invest 2010; 90: 116-27.

  4. El-Swefy S, Hassanen SI. Improvement of hepatic fibrosis by leukotriene inhibition in cholestatic rats. Ann Hepatol 2009; 8: 41-9.

  5. Friedman SL. Hepatic fibrosis-overview. Toxicology 2008; 254(3): 120-9.

  6. •ivkovic J, Mujic I, Zekovic Z, Vidovic S, Mujic A, Jokic S. Radical scavenging, antimicrobial activity and phenolic content of castanea sativa extracts. J Cent Eur Agric 2009; 10(2): 175-82.

  7. Karimi G, Hosseinzadeh H, Ettehad N. Evaluation of the gastric antiulcerogenic effects of Portulaca oleracea L. extracts in mice. Phytother res 2004; 18: 484.

  8. Cai Y, Luo Q, Sun M, Corke H. Antioxidant activity and phenolic compounds of 112 traditional Chinese medicinal plants associated with anticancer. Life Sci 2004; 74(17): 2157-84.

  9. Xiang L, Xing DM, Wang W, Wang RF, Du LJ. Review on chemical constituents of Portulaca oleracea L. Asia-Pac Trad Med 2006; 7: 64-8.

  10. Chan K, Islam M, Kamil M, Radhakrishnan R, Zakaria M, Habibullah M, Attas A. The analgesic and anti-inflammatory effects of Portulaca oleracea L. subsp. sativa (Haw.) Celak. J Ethnopharmacol 2000; 73(3): 445-51.

  11. Cui MZ, Liu H, Li CY. Changes of blood glucose in diabetic rats and the interventional effect of purslane. Chin J Clin Rehabil 2005; 27: 92-3.

  12. Lim YY, Quah EPL. Antioxidant properties of different cultivars of Portulaca oleracea. Food Chem 2007; 103: 734-40.

  13. Radhakrishnan R, Zakaria MNM, Islam MW, Chen HB, Kamil M, Chan K, Al-Attas A. Neuropharmacological actions of Portulaca oleracea L.v. sativa (Hawk). J Ethnopharmacol 2001; 76: 171-6.

  14. Wang W, Gu L, Dong L, Wang X, Ling C, Li M. Protective effect of Portulaca oleracea extracts on hypoxic nerve tissue and its mechanism. Asia Pac J Clin Nutr 2007; 16: 227-33.

  15. Rashed AN, Afifi FU, Disi AM. Simple evaluation of the wound healing activity of a crude extract of Portulaca oleracea L. (growing in Jordan) in Mus musculus JVI-1. J Ethnopharmacol 2003; 88: 131-6.

  16. Yen GC, Chen HY, Peng HH. Evaluation of the cytotoxicity, mutagenicity and antimutagenicity of emerging edible plants. Food Chem Toxicol 2001; 39: 1045-53.

  17. Yang YY, Lin HC, Huang YT, Lee TY, Lee WC, Hou MC, Lee FY, et al. Adaptive vasodilatory response after octreotide treatment. Am J Physiology 2001; 281: G117-G123.

  18. Pagar HJ, Jyothi TM, Rajendra SV, Gouda AV, Prabhu K, Setty SR. A study on preliminary phytochemical and diuretic activity of leaves of Protulaca oleracea. Pharmacog Magazine 2007; 3: 264-6.

  19. Rafatullah S, Mossa JS, Ageel AM. Hepatoprotective and safety evaluation studies on Sarsaparilla. Int J Pharmacog 1991; 29: 296-301.

  20. MacDonald S, Prenzler PD, Antolovich M, Robards K. Phenolic content and antioxidant activity of olive extracts. Food Chem 2001; 73: 73-84.

  21. Agoramoorthy G, Chandrasekaran M, Venkatesalu V, Hsu MJ. Antibacterial and antifungal activities of fatty acid methyl esters of the blind-your-eye mangrove in India. Braz J Microbiol 2007; 38: 739-42.

  22. Chang C, Yang M, Wen H, Chern J. Estimation of total flavonoid content in propolis by two complementary colorimetric methods. J Food Drug Analysis 2002; 10(3): 178-82.

  23. Blois MS. Antioxidant determinations by the use of a stable free radical. Nature 2002; 26: 1199-200.

  24. Retiman S, Frankel S. A colorimetric method for the determination of serum glutamic oxaloacetic and glutamic pyruvic transaminases. Am J Clin Pathol 1957; 28: 56-63.

  25. Belfield A, Goldberg DM. Revised assay for serum phenyl phosphatase activity using 4-amino-antipyrine. Enzyme 1971; 12: 561-73.

  26. Szasz G. A kinetic photometric method for serum γ-glutamyl transpeptidase. Clin Chem 1969; 15112-36.

  27. Berth M, Delanghe J. Protein precipitation as a possible important pitfall in the clinical chemistry analysis of blood samples containing monoclonal immunoglobulins: 2 case reports and a review of literature. Act Clin Bleg 2004; 59(5): 263-73.

  28. Marklund SL, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 1974; 47: 469-74.

  29. Aebi H. Catalase in-vitro. In: Packer L (ed.). Methods of enzymology. Vol. 105. San Diego: Academic Press Inc.; 1984, p. 121-6.

  30. Rotruck JT, Pope AL, Ganther HE, Swanson AB, Hafeman DG, Hoekstra WG. Selenium: biochemical role as a component of glutathione peroxidase. Science 1973; 179: 588-90.

  31. Beutler F, Duron O, Mikus B. Improved method for the determination of blood glutathione. J Lab Clin Med 1963; 16(6): 882-8.

  32. Uchiyama M, Mihara M. Determination of malondialdehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 1978; 86: 279-86.

  33. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-75.

  34. Corti A, Fassino J, Marcucci F, Barbenti E, Cassani G. Oligometric tumor necrosis factor −α slowly converts into the reactive forms at bioactive levels. Biochem 1992; 284: 905-10.

  35. Senedecor GW, Cochran WG. Statistical methods. 7th. Ed. Iowa, USA: Iowa Uni. Press. Ames.; 1981, p. 175-91.

  36. Al-Howiriny TA. Protective effect of ‘purslane’ on rat liver injury induced by carbon tetrachloride. Saudi pharmaceutical J 2008; 16(3-4): 239-44.

  37. Sudhakar D, Krishna Kishore R, Parthasarathy PR. Portulaca oleracea L. extract ameliorates the cisplatin-induced toxicity in chick embryonic liver. Indian J Biochem Biophys 2010; 47(3): 185-9.

  38. Ueki M, Koda M, Matono T, Sugihara T, Maeda K, Murawaki Y. Preventative and therapeutic effects of perindopril on hepatic fibrosis induced by bile duct ligation in rats. Molecular Med Rep 2009; 2: 857-64.

  39. Sagar PT, Hitesh NJ, Savita DP, Umesh MU. Hepatoprotective effect of Cocculus hirsutus on bile duct ligation-induced liver fibrosis in Albino Wistar rats. Bangladesh J Pharmacol 2009; 4: 126-30.

  40. Tieppo J, Vercelino R, Dias AS, Marroni CA, Marroni N. Common bile duct ligation as a model of hepatopulmonary syndrome and oxidative stress. Arq Gastroenterol 2005; 42: 244-8.

  41. Lee S, Kim S, Le HD, Meisel J, Strijbosch R, Nose V, Puder M. Reduction of hepatocellular injury after common bile duct ligation using omega-3 fatty acids. J Pediatric Surg 2008; 43: 2010-5.

  42. Saraf S, Ashawat MS, Saraf S. Flavonoids: A nutritional protection against oxidative and UV induced cellular damages. Pharmacog Rev 2007; 1: 30-40.




2020     |     www.medigraphic.com